[What is new in pediatric neurology?].
Some significant advances in the field of pediatric neurology are reviewed. For many constitutional disorders, concepts and diagnostic procedures have progressed from various genetic techniques or from protein labeling in situ. Many neurodegenerative disorders, some poorly-defined metabolic diseases, and several syndromes associating mental retardation with neurologic or extraneurologic malformations have been characterized. In addition, for many disorders viewed as 'poorly specific' (mental retardation, epilepsy, migraine), familial forms have permitted us to define the first genes involved. In 'acquired' disorders, new data come from clinical trials (antiepileptic, anti-inflammatory drugs) rather than definite conceptual advances. Finally, clinics and biology are no longer the only approaches to brain functions, and clinical neurophysiology could encounter a second wind thanks to the techniques of functional imaging, especially in the fields of developmental neuropsychology.
Landrieu
P
P
Service de neuropédiatrie, centre hospitalier universitaire Paris-Sud-Bicêtre, Le Kremlin-Bicêtre, France.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001921:Brain / Q000502:physiology; D002648:Child; D004827:Epilepsy / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D008607:Intellectual Disability / Q000175:diagnosis / Q000235:genetics; D008659:Metabolic Diseases / Q000175:diagnosis; D008881:Migraine Disorders / Q000235:genetics; D009422:Nervous System Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D019636:Neurodegenerative Diseases / Q000175:diagnosis; D013577:Syndrome
D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants